CD19 and lymphoma: The modified iDuo NK cells exhibited effective elimination of both CD19+ and CD20+ lymphoma cells through a combination of intrinsic cytotoxicity, anti-CD19 CAR mediated killing, and ADCC mediated by hnCD16 engagement with rituximab [166].